How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy

Daniele Armocida b,⇑, Mauro Palmieri b,⇑, Alessandro Frati a, Antonio Santoro a, Alessandro Pesce a,b

a IRCCS – "Neuromed", Pozzilli, (IS), Italy
b A.U.O. "Policlinico Umberto I", Neurosurgery Division, Sapienza University, Rome Human Neurosciences Department, Via del Policlinico, 155 – 00161 Rome, Italy

Article info
Article history:
Received 26 April 2020
Accepted 3 July 2020

Keywords:
Covid-19
Neuroscience
SARS-Cov-2
Human coronavirus
Italy
Central nervous system
Brain

Abstract
Italy is currently one of the countries most affected by the global emergency of COVID-19, a lethal disease of a novel coronavirus renamed as SARS-CoV-2. SARS-CoV-2 shares highly homologous sequence with the most studied SARS-CoV, and causes acute, highly deadly pneumonia (COVID-19) with clinical symptoms similar to those reported for SARS-CoV and MERS-CoV. Increasing evidence shows that these coronaviruses are not always confined to the respiratory tract and that they may also neuroinvasive and neuropathogenic, with potential neuropathological consequences in vulnerable populations. The aim of this study is to predict a likely CNS involvement by SARS-CoV-2 by studying the pathogenic mechanisms in common with other better known and studied coronaviruses with which it shares the same characteristics. Understanding the mechanisms of neuroinvasion and interaction of HCoV (including SARS-Cov-2) with the CNS is essential to evaluate potentially pathological short- and long-term consequences. Autopsies of the COVID-19 patients, detailed neurological investigation, and attempts to isolate SARS-CoV-2 from the endothelium of cerebral microcirculation, cerebrospinal fluid, glial cells, and neuronal tissue can clarify the role played by COVID-19 in CNS-involvement and in the ongoing mortalities as has been in the recent outbreak.

1. Introduction

Another highly pathogenic HCoV, currently called SARS-CoV-2, emerged in December 2019 in Wuhan, China, and spread rapidly around the world involving Europe and especially Italy in a dramatic way [79]. This novel HCoV has caused a national outbreak of severe pandemic pneumonia (COVID-19). The first reports about a dangerous infection emerged from December 2019 in Wuhan, China. In February 2020, a designation "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) became the official means to refer to this type of virus, and finally, the WHO officially renamed the disease as COVID-19. The complete genome of SARS-CoV-2 was successfully established as 29,903 bp single-stranded RNA (ss-RNA) SARS-like coronavirus [1]. Italy is currently one of the countries most affected by the global emergency of COVID-19.

The common onset-symptoms of COVID-19 are dry cough and fever at the onset of illness, but rapidly pathology evolves towards a respiratory distress syndrome (ARDS), and most of the patients admitted to the intensive care could not breathe spontaneously. About 46%–65% of the patients in the intensive care worsened in a short period and died due to respiratory failure [63].

As observed for the most important pandemic circulating strains of HCoVs they involve more frequently a vulnerable population (such as the elderly, immune-compromised individuals or patients with comorbidities). Additionally, it has been reported that some patients affected by SARS-CoV-2 also showed neurologic signs such as headache, nausea, and vomiting [2–4,69].

Recently, a study from Mao et al. [77] has reported neurological manifestations in COVID-19 which suggests a rationale of the neurotropic potential in the COVID-19 virus. Also, recently it was reported [70] a suspected first European case of COVID-19 associated with acute necrotizing hemorrhagic encephalopathy in a female airline worker.
A lot of studies demonstrate that HCoVs can invade the CNS [6,38,39] and that neurotropism is one common feature of these groups of virus [44]. Recent findings of an altered sense of smell or hyposmia in an un complicated early stage of COVID-19 have been reported, and these data should be investigated thoroughly for CNS involvement.

The aim of this study is to predict a likely CNS involvement by SARS-CoV-2 by studying the pathogenic mechanisms in common with other better known and studied coronaviruses with which it shares the same characteristics.

2. Material and methods

2.1. Rationale

In light of the high similarity between SARS-CoV and SARS-CoV2, the potential neuro-invasion of SARS-CoV-2 is likely linked to the acute respiratory failure of COVID-19 patients. Some studies demonstrate a critical role for infection of the CNS in severe disease in SARS-CoV-infected animals and humans [4,76].

2.2. Objective

Being that most HCoVs share a similar viral structure and infection pathway and therefore the infection mechanisms previously found for other HCoVs, it is reasonable that previously studied hypothetical mechanisms of neuro-invasion may also be applicable for SARS-CoV-2.

Based on an epidemiological survey on COVID-19, the median time from the first symptom to dyspnea was 5.0 days, and to the intensive care was 8.0 days. Therefore, given the probable neuro-invasion, the latency period is enough for the virus to enter into the neurons and the risk of SARS-CoV-2 infection may be currently underestimated. As an emerging virus no effective treatment has been developed for the COVID-19. Therefore, awareness of the possible entry of SARS-CoV-2 into the CNS will have important guiding significance for the prevention and treatment.

2.3. Eligibility criteria: sources and study selection

Therefore, while screening the literature, we adopted the following inclusion and exclusion criteria: 1) papers identifying tropism to the central nervous system of the coronavirus family; 2) detailed reports concerning mechanisms of action, clinical and laboratory evaluation 3) year of publishing was also included to understand a possible year of experience/improvement of the technological setup effect on the results;

Conversely, we excluded the following. First, we excluded articles that do not mention CSN involvement. Second, we excluded incomplete reports according to the aforementioned end points. Because accurate reports are extremely few, and among them, some focused predominantly on the involvement of respiratory tract and clinical surveillance, we decided to include in this review those reports in which at least 1 of the 2 key point about this topic of the present study were reported in detail.

2.4. Information sources

The English literature was systematically investigated using MEDLINE, the NIH Library, PubMed, and Google Scholar. The last search date was April 18, 2020. The following search terms were used: SARS-CoV central nervous system, SARS-CoV brain, coronavirus central nervous system, COVID-19 central nervous system and brain.

Backward citation tracking was applied to identify articles not retrieved by electronic searches. The search returned a total of 80 papers, 17 including review, 2 clinical trial and 61 laboratory study analysis.

To this initial cohort, the aforementioned exclusion criteria were applied, accordingly eliminating a total of 11 papers (Fig. 1). To this cohort of patients, the personal experience of our department and articles and case reports that hypothesize the specific involvement of SARS-CoV-2 of the CNS of the present paper were added, resulting in a total final cohort composed of 80 papers.

3. Discussion

3.1. The human coronaviruses naturally reach the central nervous system

Following the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), another highly pathogenic coronavirus named SARS-CoV-2 rapidly spreads around the world. Human coronaviruses (HCoVs), which are large enveloped non-segmented positive-sense RNA viruses, generally cause enteric and respiratory diseases in animals and humans [57].

HCoVs are typically classified in two groups: Alphacoronavirus (of which the most representative is HCoV-229E) and Betacoronavirus (HCoV-OC43, SARS-and MERS-CoV) 24

HCoVs can reach the lower respiratory tract and, as opportunistic pathogens [14,65,66], be associated with more severe illnesses, such as bronchitis, bronchiolitis, pneumonia and ARDS as it happened for SARS-CoV and MERS-CoV, has called global attention to the lethal potential of HCoVs [58]. So, genomic analysis and public evidence show that SARS-CoV-2 is in the same Betacoronavirus group as MERS-CoV and SARS-CoV, which shares a highly homologous sequence with SARS-CoV [59], and shares similar pathogenesis [60]. Moreover, the entry of SARS-CoV-2 into human host cells has been identified to use the same entry receptor as SARS-CoV, suggesting the likelihood of the same population of cells being targeted and infected [25,61,62,71].

The entry of SARS-CoVs into human host cells is mediated mainly by a cellular receptor angiotensin-converting enzyme 2 (ACE2) which is expressed in human airway epithelia, lung parenchyma, vascular endothelia, kidney cells, and small intestine cells.

Fig. 1. A prisma Flow-diagram for selection of studies.
Primary viral replication takes place in the mucosal epithelium of upper respiratory tract (nasal cavity and pharynx), with further multiplication in the lower respiratory tract and gastrointestinal mucosa [72], giving rise to a mild viremia.

Dissimilar to SARS-CoV, SARS-CoV-2-infected patients rarely showed prominent upper respiratory tract signs and symptoms, but manifest an exuberant inflammatory response during SARS-CoV-2 infection, further resulting in uncontrolled pulmonary inflammation, likely a leading cause of case fatality, indicating that the target cells of SARS-CoV-2 may be located in the lower airway [58]. Rapid viral replication and cellular damage, virus-induced ACE2 downregulation and shedding, and the antibody-dependent enhancement (ADE) are responsible for the development of an aggressive inflammation caused by SARS-CoV-2 [71]. The initial onset of rapid viral replication may trigger the production of exuberant pro-inflammatory cytokines and chemokines. A possible underlying mechanism of antibody-dependent enhancement (ADE) has been proposed recently [71] as the phenomenon that can promote viral cellular uptake of an infectious virus–antibody complexes following their interaction with Fc receptors (FcR), FcγR, or other receptors, resulting in enhanced infection of target cells. The interaction of FcγR with the virus-anti-S protein-neutralizing antibodies (anti-S-IgG) complex may facilitate both inflammatory responses and persistent viral replication in the lungs [25,71].

Viral involvements of the CNS are rare and often the clinical surveillance focus on a few different viruses such as HSV, arboviruses, and enteroviruses [10], but HCoVs also have a recognized ability to invade the CNS, where they can infect the neurons [3], but their incidence in clinical practice is difficult to evaluate [11]. HCoVs can naturally reach the CNS in humans and could potentially be associated with neurological symptoms [6,25,28,33]. These ubiquitous human pathogens are molecularly related in structure and mode of replication that is the same for every type [16–20].

3.2. The route to the CNS

Over the years, HCoVs have also been identified as possible etiological agents for pathologies outside the respiratory tract [25–27] and a propensity, under certain conditions, to invade the CNS [57,64] and induce neurological diseases [28–30]. However, the exact route by HCoVs enters the CNS is still not completely understood. HCoV may enter the CNS through different hypothesized ways.

The main theory affirm that SARS-CoV probably uses as the main entry route into the CNS the olfactory nerve fibers [4,15,31,32,48], and induces neuronal cell death [4]. In the human airways, after an intranasal infection, although the olfactory bulb is highly efficient to controlling viral neuro-invasion, HCoVs have been shown to enter CNS through the olfactory route (OR) [41–43] (in same pathway both animal and humans [22,23]).

The virus in the general circulation enables it to pass into the cerebral circulation where the sluggish movement of the blood within the microcirculation combined with the high rate of load in initial sites of infection could be one of the factors make possible the interaction of the COVID-19 virus spike protein (S-protein) with ACE2 expressed in the capillary endothelium. Subsequent budding of the viral particles from the capillary endothelium, spreading along the Virchow–Robin spaces surrounding arterioles and venules [2,44], and disseminates to several different regions of the brain and the brainstem [39,43].

The second hypothesized pattern of spreading within the CNS is through neuronal dissemination, where a given virus infects neurons in the periphery using the mechanisms of active transport within those cells to gain access to the CNS [39,40,44,50,52]. Seems that HCoV could move along the axon using the anterograde axonal transport between neurons without an effective inflammation of tissue [49]. Other details are described in the schematic draw (Fig. 2).

SARS-CoV, also demonstrates a potential myeloid cell invasion [34–36] and an ability to manipulate the innate immunity and to disseminate to other tissues, including the CNS [37]. Moreover, persistently-infected leukocytes may serve as a reservoir and vector for neuroinvasive HCoV [38]. Although HCoV infections are, most of the time, restricted to the airways, they may under poorly understood conditions extend over the epithelium barrier and could use the hematogenous route propagate towards the CNS [33]; However, the hematogenous or lymphatic route seems impossible, especially in the early stage of infection, since almost no virus particle was detected in the non-neuronal cells in the infected brain areas [68].

Specifically for COVID-19, the possible neuro-invasion of SARS-CoV-2 may also partially explain why some of the patients developed respiratory failure. It is possible that most of the persons in Wuhan, who were the first exposed to this previously unknown virus, did not have any protective measure so that the mortality rate in Wuhan was higher than in other cities in China. On the other hand, is hard to explain the high number of deaths and critical patients in Italy. If the neuro-invasion of SARS-CoV-2 does play a role in the development of respiratory failure in COVID-19 patients, the precautionary use of masks could be considered as the most effective measure to protect against the possible entry of the virus into the CNS. The presence of HCoVs viral particles...
has been reported in the brains of patients and experimental animals, where the brainstem was heavily infected. In light of the similar nature between SARS-CoV and SARS-CoV2, the potential invasion of SARS-CoV2 is likely partially responsible for the ARDS in COVID-19 patients. Awareness of this will have important guiding significance for the prevention and treatment of the SARS-CoV-2-induced respiratory failure. Besides all these issues, accumulating evidence from the medical world strongly suggests that, being opportunistic pathogens, these viruses can escape the immune response and spread to the CNS [12,13].

### 3.3. Possible mechanisms

The brain has been reported to express ACE2 receptors that have been detected over glial cells and neurons, which makes them a potential target of SARS-CoVs where its interaction with ACE2 receptors expressed in neurons can initiate a cycle of viral budding [21]. SARS-CoV-2, like SARS-CoV, uses other mRNA encoding several receptors expressed in neurons can initiate a cycle of viral budding a potential target of SARS-CoVs where its interaction with ACE2 receptor.

Viral budding in the brain can be accompanied by neuronal damage without substantial inflammation, or by a large endothelial rupture in cerebral capillaries accompanied by bleeding within the cerebral tissue [22]. The role of the blood–brain barrier (BBB) in containing the virus and preventing it from gaining access to the neural tissues [9] and type of spreading needs to be further explored. The presence of ACE2 or DPP4 solely is not sufficient to make host cells susceptible to infection. For example, some ACE2-expressing endothelial cells failed to be infected by SARS-CoV [67]. Likewise, the infection of SARS-CoV or MERS-CoV was also reported in the CNS, where the expression level of ACE2 or DDP4 is very low under normal conditions.

ACE2 binding affinity of the SARS-CoV-2 S-protein ectodomain was 10–20-fold higher than that of the SARS-CoV S-protein, which may be the reason for the higher binding affinity of the COVID-19 S-protein to the human ACE2 receptor in lower respiratory tract.

The structural proteins S and E proteins are actually considered the most important factor of neurovirulence and propagation in virus-cell interactions [6,50,52]. S proteins (in particular S2 and S5 domain), play a significant role in viral dissemination and influence the rate and success of virus propagation towards the brain [44].

It's reported that a single point mutation in S-protein of HCoV-OC43 modulates virus-induced neuropathology in a mouse model from encephalitis to an MS-like paralytic disease related to glutamate excitotoxicity, with the involvement of AMPA receptors [73]. It was demonstrated that glutamate receptors are also involved in the infection of mice with HCoV-OC43. Possible glutamate excitotoxicity, thus increasing damage to neurons and/or disturbing glutamate homeostasis [6,7] and thereby contributing to neuronal degeneration and hind-limb paralysis and possible demyelination [44].

It is also possible that excessive levels of proinflammatory cytokines/chemokines in the brain result in a “cytokine storm” that can lead to harmful effects in the brain and other tissues. To support this hypothesis, three cytokines often associated with immunopathology, IL-1, tumor necrosis factor-alpha, and IL-6, are all upregulated in the brains of infected K18-hACE2 mice [76]. IL-6 was produced by a normal consequence of infected neurons and in the adult brain following ischemia in an unknown mechanism. Probably, IL-6 may be induced by another inflammatory mediator, such as IL-1 or tumor necrosis factor alpha [78], also expressed in the SARS-CoV-infected CNS.

Given this high-level expression of proinflammatory mediators, the lack of inflammation that we often observe in the CNS is surprising [38].

One possibility is that the virus interferes with the initiation of the immune response is not known at present but may be one mechanism that would result in a diminished inflammatory response [33,44].

The other one is that the degeneration of neurons may success-fully lead to the induction of different regulated cell death (RCD) pathways [34,53], similar of what observed after infection by other respiratory viruses [50,51].

### 4. Limitations and future studies

In the SARS-CoV infections that were reported in the past, autopsy findings of the patients have shown strong shreds of evidence of the presence of SARS-CoV by electron microscopy, immunohistochemistry, and real-time reverse transcription-PCR. Patients with acute SARS-CoV illness have also demonstrated the presence of the virus in cerebrospinal fluid [5], but currently, due to high health security measures, there is no availability of autopsy studies.

In conclusion, there is not a clear cause–and–effect relationship with the onset of neurological symptoms in COVID-19 patients, though recent reports associated cases of CNS-involving [6,8,9,28]. HCoV may potentially persist in the human CNS as it does in murine models and potentially be associated with different types of long-term sequelae and chronic human neurological diseases [45–47]. Such questions deserve timely investigations.

Viral encephalitis is often caused by herpes simplex and other types of viruses [74,75]. The brain lesions are often hemorrhagic [54], and a rare complication is a large intracerebral hematoma which usually implies a poor prognosis. For this reason MRI can be a perfect tool to identify a viral propagation in brain [74,75].

The prognosis of viral encephalitis is usually poor, but early treatment with antiviral agents has been proven to be efficacious, the challenge is that with such a rapid worsening of onset symptoms that required assisted ventilation, COVID-19 patients are often not neurologically evaluable and therefore it is difficult to discriminate which of them would indicate to perform neuroimaging. Furthermore, the potential neurological significance of the typical hypo-agesia and hypo-anosmia of COVID-19 [14] was until now, systematically investigated through MRI imaging.

Actually we don't know how viral factors (mutations in specific virulence genes), host factors (immunodepression, age) or a mixture of both (underlining the importance of virus–host interactions) [39,55,56] can explain the access of HCoV to the CNS. Autopsies of the COVID-19 patients, detailed neurological investigation, and attempts to isolate SARS-CoV-2 from the endothelium of cerebral microcirculation, cerebrospinal fluid, glial cells, and neuronal tissue would clarify the role played by this novel COVID-19 causing coronavirus in the ongoing mortalities as has been in the recent outbreak.

### 5. Conclusion

The neurotropic potential of SARS-CoV-2 in patients reported in the recent outbreak of COVID-19 has to be considered as a potentially serious threat for all health care systems, worldwide. Accumulating evidence indicates that HCoVs are neuroinvasive in humans and we hypothesize represent an important proportion of CNS viral infection associated with encephalitis, meningitis, myelitis, and long-term neurological disorders, either as a result of inadequate host immune responses and/or viral propagation in the CNS and for this reason COVID-19 will need to be studied for a long time even after the Italian and European health emergency is overcome to avoid possible other fearsome consequences for public health. Understanding the mechanisms of neuroinvasion...
and interaction of SARS-HCoV-2 with the CNS is essential to evaluate potentially pathological short- and long-term consequences. Antiviral therapy should be carried out as early as possible and it is also urgent to find effective antiviral drugs that can cross the BBB.

Compliance with ethical standards

Funding: This study was not funded by any association.

Conflict of interest: We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Informed consent: Informed consent was obtained from all individual participants included in the study.

The patient has consented to the submission of this review article to the journal.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email.

References

[1] Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome. Nucleotide, National Center for Biotechnology Information (NCBI), National Library of Medicine (US), National Center for Biotechnology Information, Bethesda, MD, https://www.ncbi.nlm.nih.gov/sutils/nuccore/1798174254.
[2] Palasca O, Santos A, Stolte C et al. ISSUES 2.0: an integrative web resource on mammalian tissue expression. Database 2018, No. bay003.
[3] Bate JR Jr. Virus and Immune-mediated encephalitides: epidemiology, diagnosis, treatment, and prevention. Pediatr Neurol 2015;53:3–12.
[4] Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008;82(15):7264–75.
[5] Baig AM, Khaleeq A, Ali U. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020.
[6] Desforges M, Le Coupanceau A, Dubéau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 2019;12(1):14.
[7] Desforges M, Le Coupanceau A, Shodola JK, et al. Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res 2014;194:145–58.
[8] Spinak MA, Murphy KB, OC. Viral encephalitis. Neurol Clin 2018.
[9] Tyler KL, Acute viral encephalitis. N Engl J Med 2018;376(9):557–66.
[10] Mailes A, Stahl JP, Bloch KC. Update and new insights in encephalitis. Clin Microbiol Infect 2017;23:607–13.
[11] Biggio L, Reineck LA, Arenzetti DM. Viral infections of the central nervous system: a case-based review. Clin Med Res 2009;7:142–6.
[12] McGavern DB, Kang SS. Investigating viral infections in the nervous system. Nat Rev Immunol 2011;11:318–29.
[13] Bohnenkow K, Calvez VM, Demuth M, Kalergis AM. Neurologic alterations due to respiratory viral infections. Front Cell Neurosci 2018:12:386.
[14] Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome?. Rhinology 2020;2.
[15] Munster VJ, Prescott JB, Bushmaker T, et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Sci Rep 2012;2:736.
[16] Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol 2005;287:1–30.
[17] Greg AS, Mitchell D, Corner AH, Bannister GL, Meads EB, Julian RJ. A Hemagglutinating virus producing encephalomyelitis in Baby Pigs. Can J Comp Med Vet Sci 1962;26:49–56.
[18] Foley JE, Lapointe JM, Kolkub P, Poland A, Pedersen NC. Diagnostic features of clinical neurologic feline infectious peritonitis. J Vet Intern Med 1998;12:415–23.
[19] Foley JE, Rand C, Leutenegger C. Inflammation and changes in cytokine levels in neurologic feline infectious peritonitis. J Feline Med Surg 2003;5:313–22.
[20] Lampert PW, Sims JK, Knaizeff AJ. Mechanism of demyelination in JHM virus encephalomyelitis. Electron microscopic studies. Acta Neurochir 1973;24:76–85.
[21] Bender SJ, Weiss SR. Pathogenesis of murine coronavirus in the central nervous. J Neuroimmun Pharm 2010;5:336–54.
[22] Cowley TJ, Weiss SR. Murine coronavirus neuropathogenesis: determinants of virulence. J Neurovirol 2010;16:427–34.
[23] Hosking MP, Lane TE. The pathogenesis of murine coronavirus infection of the central nervous system. Crit Rev Immunol 2010;30:119–30.
[24] Fairley MC, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202:415–24.
[25] Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL, MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014;5:58–62.
[26] Risko H, Hovi T. Coronavirus infections of man associated with diseases other than the common cold. J Med Virol 1980;6:259–65.
[27] Morfopoulos S, Brown JR, Davies EG, et al. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 2016;375:497–8.
[28] Arbour N, Day R, Newcombe J. Neuroinvasion by human respiratory coronaviruses. J Virol 2000;74:8913–21.
[29] Cristallo A, Gambero F, Biamonti G. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol 1997;20:105–14.
[30] Chilvers MA, McKean M, Ruitman A, Myint BS, Silverman M, O’Callaghan C. The effects of coronavirus on human nasal ciliated epithelial tissue. Eur Respir J 2001;18:965–70.
[31] Djukanov R, Jelbody MF, Dijkxhoorn SM. Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J Virol 2013;87:6081–90.
[32] Desforges M, Milleti TC, Gagnon M. Activation of human monocytes after infection by human coronavirus 229E. Virus Res 2007;130:228–40.
[33] Mesel-Lemoine M, Millet J, Vidalain PO, et al. A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes. J Virol 2012;86:7577–47.
[34] Wentworth DE, Tresnan DB, Turner RC, et al. Cells of human aminopeptidase N (CD13) transgenic mice are infected by human coronavirus-229E in vitro, but not in vivo. Virology 2003;355:185–97.
[35] Spiegel M, Weber F. Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus. Virology 2006;3:17.
[36] Lassig C, Sanchez CM, Egerbacher M, Walter I, Majer S, Kolbe T, et al. Development of a transgenic mouse model susceptible to human coronavirus 229E. PNAS 2005;102:8277–80.
[37] Arbour N, Day R, Newcombe J, Talbot Pj. Neuroinvasion by human respiratory coronaviruses. J Virol 2000;74:8913–21.
[38] Brenchley JM, Comp MC, Churchyard GJ, et al. HIV infection and the central nervous system. Cell Host Microbe 2013;11:318–29.
[39] Berth SH, Leopold PL, Morfini GN. Influenza viral neuronal dysfunction and degeneration. Front Biosci 2009;14:5239–59.
[40] Mori I, Nishiyama Y, Yokochi T, Kimura Y. Olfactory transmission of SARS-HCoV-2. Front Cell Neurosci 2020;13:379–93.
[41] Durrant DM, Ghosh S, Klein RS. The olfactory bulb: an immunosensory effector organ during neurotropic viral infections. ACS Chem Neurosci 2016;7:464–9.
[42] Jacony H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology 2003;315(1):20–33.
[44] Dube M, LeCounpec A, Wong AHM, et al. Axonal transport enables neuroto- neuron propagation of human coronavirus OC43. J Virol 2018:92.
[45] Turgay C, Emine T, Ozlem K, Muhammet SP, Haydar AT. A rare cause of acute flaccid paralysis: human coronaviruses. J Pediatr Neurosci 2015;10:280–1.
[46] Lai KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004;10:342–4.
[47] Sharma K, Tengsupakul S, Sanchez O. Guillain-Barre syndrome with unilateral peripheral facial and bulbar palsy in a child: a case report. SAGE Open Med Case Rep 2019:7.
[48] Tseng SS. SARS, avian flu, bioterror: infection control awareness for the optometrist. Clin Exp Optom 2007;90:31–5.
[49] Tomishima MJ, Enquist LW. In vivo egress of an alpha herpes virus from axons. J Virol 2002;76:8310–7.
[50] Jacomy H, Fajrjose G, Almazan G, Mushynski WE, Talbot PJ. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/c mice. Virology 2006;349:335–46.
[51] Espinoza JA, Bohnwald K, Cespedes PF, et al. Impaired learning resulting from respiratory syncytial virus infection. PNAS 2013;110:9112–7.
[52] Jacomy H, Jean JR, Brison E. Mutations in the spike glycoprotein of human coronavirus OC43 modulate disease in BALB/c mice from encephalitis to flaccid paralysis and demyelination. J Neurovirol 2010;16:279–93.
[53] Favreau DJ, Desforges M, St-Jean JR. A human coronavirus OC43 variant harboring persistence-associated mutations in the S glycoprotein differentially induces the unfolded protein response in human neurons as compared to wild-type virus. Virology 2009;395:255–67.
[54] Talbot PJ, Desforges M, Brison E. Coronaviruses as encephalitis-inducing infectious agents. In: Tkachev S, editor. Non-Flavirus Encephalitis. InTech: London, UK; 2011. p. 185–202.
[55] Koch R. The Aetiology of Tuberculosis: A Translation of Die Aetiologie der Tuberculose (1882); Dover Publications: New York, NY, USA, 1942.
[56] Fredericks DN, Belman DA. Sequence-based identification of microbial pathogens: A reconsideration of Koch’s postulates. Clin Microbiol Rev 1996;9:18–38.
[57] Glass WC, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 2004;173:4030–9.
[58] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[59] Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect 2020.
[60] Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019;pii: E59.
[61] Lu R, Zhao X, Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020. in press.
[62] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020.
[63] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13.
[64] Li K, Wohlford-Lenee C, Perlman S, et al. Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase IV. J Infect Dis 2016;213:712–22.
[65] Mattern T, Scholtz W, Feller AC, Flad HD, Unluer A. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol 1991;33:737–48.
[66] Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53–73.
[67] Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003;200:282–9.
[68] Xu J, Zhong S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis 2005;41:1089–96.
[69] Rothe C, Schunk M, Soehmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020. in press.
[70] Poyiadji N, Shahin G, Nosajin D. COVID-19-associated Acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020;310:187.
[71] Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020.
[72] Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158(6):1831–1833.e3.
[73] Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitoto- toxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. J Virol 2011;85:12464–73.
[74] Noguchi T, Yoshiura T, Hiwatashi A, et al. CT and MRI findings of human herpesvirus 6-associated encephalopathy: comparison with findings of herpes simplex virus encephalitis. Am J Roentgenol 2010;194:754–60.
[75] Sawlani V. Diffusion-weighted imaging and apparent diffusion coefficient evaluation of herpes simplex encephalitis and Japanese encephalitis. J Neurol Sci 2009;287:221–6.
[76] Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitoto- toxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. J Virol 2011;85:12464–73.
[77] Noguchi T, Yoshiura T, Hiwatashi A, et al. CT and MRI findings of human herpesvirus 6-associated encephalopathy: comparison with findings of herpes simplex virus encephalitis. Am J Roentgenol 2010;194:754–60.
[78] Sawlani V. Diffusion-weighted imaging and apparent diffusion coefficient evaluation of herpes simplex encephalitis and Japanese encephalitis. J Neurol Sci 2009;287:221–6.
[79] McCray Jr PB, Pewe L, Wohlford-Lenee C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 2007;81:813–21.
[80] Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv, 2020.02.22.20026500.
[81] Carmen J, Rothstein JD, Kerr DA. Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis. Brain Res 2009;1263:143–54.
[82] Jin Y, Yang, Ji W. Virology, epidemiology, pathogenesis, and control of COVID- 19. Viruses 2020;12(4).

Further reading

[24] Myint SH. In: The coronaviridae. Boston, MA: Springer US; 1995. p. 389–401.